NPRL2 gene therapy is effective in overcoming cisplatin resistance in NSCLC, but the antitumor immune response and the effectiveness of NPRL2 have not been studied on ICB-resistant KL (KRAS & LKB1/STK11 co-mutant) tumors. This evidence concerns the gene NPRL2 and non-small cell lung carcinoma.